Industry analysis from MarketsandMarkets indicates that the market valuation will climb from $1.11 billion in 2026. This growth is underpinned by substantial R&D investments from pharmaceutical and biotechnology companies, alongside an increasing demand for specialized proteins in areas like oncology, immunology, and stem cell research. North America remains the dominant region, capturing 43.6% of the market share in 2025 due to its advanced life science infrastructure and established research institutions.

Within the product landscape, cytokines and chemokines serve as the primary drivers, accounting for 25.9% of the market. These proteins are essential for cell signaling and differentiation studies. Mammalian expression systems currently lead the host-cell segment, favored for their ability to produce complex proteins with human-like folding and post-translational modifications. Major market players, including Thermo Fisher Scientific, Bio-Techne, and Merck KGaA, continue to compete alongside specialized firms and startups to refine protein stability and lot-to-lot consistency for sensitive experimental applications.